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ABSTRACT
Major histocompatibility complex class II (MHCII) mol-
ecules are heterodimeric surface proteins involved in
the presentation of exogenous antigens during
the adaptive immune response. We demonstrate the
existence of a fine level of regulation, coupling the
transcription and processing of mRNAs encoding a
and b chains of MHCII molecules, mediated through
binding of their Untraslated Regions (UTRs) to the
same ribonucleoproteic complex (RNP). We propose
a dynamic model, in the context of the ‘MHCII RNA
operon’ in which the increasing levels of DRA and
DRB mRNAs are docked by the RNP acting as a
bridge between 50- and 30-UTR of the same messen-
ger, building a loop structure and, at the same time,
joining the two chains, thanks to shared common pre-
dicted secondary structure motifs. According to cell
needs, as during immune surveillance, this RNP
machinery guarantees a balanced synthesis of DRA
and DRB mRNAs and a consequent balanced surface
expression of the heterodimer.
INTRODUCTION
Major histocompatibility complex class II molecules
(MHCII) are cell-surface glycoproteins that play a
pivotal and essential role in the regulation of the
adaptive immune response, as they induce development,
activation and survival of CD4 T cells, through presenta-
tion of extracellular antigens (1).
MHCII are expressed by different cell types named
antigen-presenting cells (APCs), which are distinguished
into two major categories on the basis of their potential
for antigen presentation: professional or non-professional.
Professional APCs are cells of haematopoietic origin
specialized in the priming of naı¨ve T cells and include
dendritic cells, B lymphocytes and cells of monocyte/
macrophage lineage (2). Non-professional APCs are
non–bone marrow-derived cells that constitutively
express MHCII molecules but do not have a complete
range of co-stimulatory molecules, such as thymic epithe-
lial cells (3) and endothelial cells in various organs, as well
as cell types that do not have basal levels of MHCII mol-
ecules but can be induced in response to interferon-g (4).
This category also includes tumour cells from several solid
neoplastic tissues, where it is not surprising to find CD4 T
helper lymphocytes specific against tumour antigens
MHCII-restricted. The level of expression of MHCII mol-
ecules on the surface of APCs is strictly related to the
functioning of the immune response in infection, trans-
plantation, cancer and autoimmunity (5).
MHCII genes encode the polymorphic human leuco-
cyte antigens (HLA): HLA-DR, HLA-DQ and HLA-DP
proteins, present as a and b heterodimers on the cell
surface, and their expression is mainly regulated at the
level of transcription by a highly conserved regulatory
module site in the promoters of the genes in all vertebrate
species. Four key trans-acting factors, constitutively
expressed, bind these modules while the cell-specific,
cytokine-induced and developmentally regulated expres-
sion of MHCII genes is ensured by Class II
Transactivator (CIITA), the master key transcriptional
activator that mediates its function not through a direct
binding to DNA but through interaction with the proteins
of enhanceosome (6). This complex machinery guarantees
a coordinated transcriptional regulation of all MHCII
genes; so far no data are available for post-transcriptional
events. Recent evidence from our laboratory
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demonstrated that mRNAs encoding DR and DQ
isotypes are assembled in the cytoplasm in a functional
unit defined ‘MHCII RNA operon’ in which the 30-
UTRs of different transcripts bind the same ribo-
nucleoproteic complex (RNP), among which we have
identified two proteins: ErbB3 Binding Protein 1 (EBP1)
and Nuclear Factor 90 (NF90) (7). Both factors are well
characterized RNA-binding proteins that can influence
mRNA in terms of stability and translation (8,9) and
can also act on the transcriptional expression of the
same gene (10,11).
In this work, by interfering with the physiological
equilibrium between DRA and DRB transcripts, we
found that the ectopic expression of one mRNA influences
the transcription of the other endogenous mRNA. We
investigated the stoichiometric balance between messen-
gers encoding a and b chains and the maintenance of
the equilibrium, already established with transcription,
to determine whether this mechanism is preserved during
all steps of mRNA processing up to the surface expression
of proteins. We found that a coordinated modulation
occurs and is mediated through the presence of 50- and
30-UTR signals that physically bind proteins of the RNA
operon.
MATERIALS AND METHODS
Reagents, cell lines and flow cytometry analysis
M14 and Raji, a human melanoma and a human B
lymphoma cell line, respectively, were cultured in RPMI
1640 medium, whereas HeLa, a human epithelial cell line,
was cultured in Dulbecco’s modified Eagle’s medium, both
media supplemented with 10% Foetal Calf Serum (FCS).
Primary monocytes were prepared from buffy-coat of a
healthy donor. The peripheral blood mononuclear cells
recovered by centrifugation over Ficoll Paque Plus
(Amersham Biosciences) gradient were further purified
by a multistep Percoll gradient, obtaining a monocyte
80% pure population, as assessed by flow cytometry
with an anti-CD14 antibody (data not shown). To
measure the mRNA half-life, actinomycin D (Act D)
(10 mg/ml) was added to cell cultures after 48 h from trans-
fection for 2, 4 and 6 h.
Determination of cell surface expression of MHCII
antigens was performed by cytofluorimetric analysis
using the FACSAria cell-sorting system and analysed by
the DIVA software (BD Biosciences). Fluorescein isothio-
cyanate (FITC) mouse anti-human HLA-DR and CD14,
along with the appropriate FITC mouse IgG isotype
control, were purchased from BD Biosciences.
Transfections
All plasmids used were prepared by cloning cDNAs
in pSVK3 expression vector and are represented in
Supplementary Table S1 and described in Supplementary
Methods.
Silencing of EBP1 and NF90 was performed with
siRNAs and procedures previously described (7), and
transfection of p5DRA3 and p5DRB3 was carried out
24 h after silencing. For mRNA recovery, cells were
harvested at 6, 18 and 42 h after transfection (correspond-
ing to 30, 48 and 72 h from the beginning of the experi-
ment, respectively).
M14 stable transfectants were carried out by transfec-
tion of CMV10-3 FLAG vector containing cDNA
encoding EBP1 p48 isoform, kindly provided by Prof A.
Hamburger (12).
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) assay was per-
formed as described previously (13), with several modifi-
cations reported in Supplementary Methods. In all,
1.5 106 M14 cells were transfected with 4 mg of pSVK3,
p5DRB3 and p5DRB, and the cells were harvested after
48 h. The pre-cleared chromatin was immunoprecipitated
with 5 mg of anti-RNA Pol II C-terminal repeat domain
P-S5 antibody (Abcam). One-tenth of the immunopre-
cipitated DNA and input DNA were analysed by quanti-
tative reverse transcriptase–polymerase chain reaction
(qRT–PCR) using DRA-c-F and DRA-c-R promoter
primers (Supplementary Table S2).
All Ct values were normalized to their own input and
are expressed as 2Ct between sample immunopre-
cipitated with anti-PolII and with rabbit anti-IgG (14).
The values obtained were further normalized to pSVK3,
considered equal to one.
RNA quantization and riboprobes synthesis
For the isolation of total RNA, after lysis of cells in
QIAzol Lysis Reagent (QIAGEN), the total RNA was
purified using phenol–chloroform extraction. All RT reac-
tions were performed using the QuantiTect RT Kit
(QIAGEN). Nucleus–cytoplasmic RNA preparation was
carried out 48 h after transfection by PARIS kit from
AMBION. The amount of specific transcripts was
measured by qRT–PCR, through the DNA Engine
Opticon Real-Time PCR Detection System (BIORAD),
using the amount of cDNA obtained retro-transcribing
0.5mg of total RNA. The QuantiTect SYBR Green PCR
Kit (QIAGEN) was used to perform all the reactions in
presence of 0.2 mM primers (Supplementary Table S2),
synthesized by PRIMM; each assay was run in triplicate.
All DNA fragments used for the riboprobes synthesis
were prepared as previously described (7) or were obtained
by PCR, using full-length cDNAs as template and the
primers indicated in Supplementary Table S2. The tran-
scription reactions were performed to obtain cold
biotin-conjugated CTP and [32P] UTP-labelled riboprobes
using T7 in vitro transcription system MAXIScript T7
(Ambion). 5DRA, 5DRB, 3DRA and 3DRB templates
are the 50- and 30-UTRs of the corresponding cDNAs,
synthesized by primers listed in Supplementary Table S2.
5DRA and 5DRB templates were obtained by enzyme
digestion of 5DRA construct with AvaI and 5DRB con-
struct with BsmAI (see sequences in Supplementary Data).
Ubiquitin-conjiugated enzyme (UBC) template negative
control corresponds to 122 nt of the 30-UTR.
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Pull-down and 50–30 co-precipitation assays
In all, 120 mg of cytoplasmic proteins were incubated for
30 min at room temperature with 1 mg of biotinylated tran-
scripts in TENT-binding buffer (10mM Tris–HCl pH 8,
1mM ethylenediaminetetraacetic acid, pH 8, 250mM
NaCl, 0.5% v/v Triton X-100). RNPs were isolated with
streptavidin-conjugated Dynabeads (Invitrogen); beads
were washed three times with TENT, and proteins were
separated by sodium dodecyl sulphate polyacrylamide
gel electrophoresis (SDS–PAGE). The presence of NF90
protein was verified by western blot analysis with specific
anti-DRBP76 (anti-double stranded RNA binding protein
76 or anti-NF90) antibody (BD Biosciences), whereas the
presence of EBP1 protein was confirmed by anti-
FLAG-M2 (Sigma) and anti-EBP1 (Abcam) antibodies.
To carry out 50–30 co-precipitation assay, 300 ng of
biotinylated RNA was bound to 2 ml of streptavidin-
conjugated Dynabeads for 60min at room temperature
in the following buffer: 14mM HEPES, pH 7.5, 6mM
Tris–HCl, pH 7.5, 60mM KCl, 1mM dithiothreitol,
1mM ethylenediaminetetraacetic acid and 1U RNase
OUT. The 32P-labelled RNA (10 ng) was incubated
with bovine serum albumin (BSA) or with increasing
amount of rEBP1 or rNF90 (0, 0.1, 0.2, 0.4, 0.8 and
1 mg), in presence of 1U of RNase OUT and 1 mg of
yeast tRNA, or 30min at room temperature. The
reaction mixtures were combined and incubated for add-
itional 40min. The beads were collected by centrifugation
and washed with buffer containing 50mM Tris–HCl,
pH7.5, 300mM KCl, 1mM MgCl2 and 0.05% NP40.
The RNA was released from the beads and analysed on
a 7 M urea and 6% Tris/Borate/EDTA acrylamide gel
(15). The radioactive images were acquired by Typhoon
analysis (Amersham Bioscience).
Computational search for common motifs
To determine whether there are common stem–loops
between the 50- and 30-UTRs of HLA-DRA (ENSG00
000228987) and HLA-DRB (ENST00000360004), a
Foldalign analysis was performed. The Foldalign algo-
rithm simultaneously folds and aligns pairs of RNA se-
quences to give either local or global structural alignments
(16). Significant local alignments for motifs common
between the sequences were then filtered; hence, only
alignments with >50% sequence identity were included.
The RNA-binding proteins NF90 and EBP1 contain
sequence/structure-specific domains; therefore, there is a
likely requirement for sequence as well as structural simi-
larity between motifs.
Statistical analysis
All results shown are the mean of three independent ex-
periments. Statistical analysis was performed using the
unpaired Student’s t-test with two-tailed distribution and
two sample equal variance parameter. In the figures,
asterisk corresponds to P< 0.05 and double asterisk cor-
responds to P< 0.01.
RESULTS
Ectopic expression of cDNA encoding a single a or b
chain modulates the level of MHCII surface heterodimer
Plasmids pSVK3, p5DRA3, p5DRA, pDRA3,
pDRA, p5DRB3 and p5DRB (Supplementary
Table S1) were transiently transfected into M14 melanoma
cell line that constitutively expresses low levels of MHCII
molecules, and the variation of surface expression of HLA-
DR heterodimers was measured after 48 h by fluorescence-
activated cell sorting analysis. Surprisingly, we observed
(Figure 1A) that after transfection of a single full-length
DRA or DRB cDNA, the surface expression of entire DR
heterodimer is increased by 2-fold if compared with cells
transfected with pSVK3 empty control (P< 0.05 and
P< 0.01, respectively). We did not observe this phenom-
enon when we transfected DRA or DRB cDNAs 50- and/
or 30-UTR deleted, indicating an involvement of these
regions in the modulation of HLA-DR surface expression
(Figure 1A).
To assess whether the surface increase of DR molecule
corresponds to an equal one of mRNA synthesis, we also
looked at the variations of HLA-DRA and HLA-DRB
transcripts by qRT–PCR. At 48 h from transfection of
the full-length p5DRA3, we observed a 14-fold increase
in the amount of HLA-DRA mRNA and a relative
13-fold augmentation of the endogenous HLA-DRB
mRNA. The same result was obtained when we trans-
fected p5DRB3 (Figure 1B). In contrast, after p5DRA
pDRA3 and pDRA transfections (Figure 1B), the
analysis revealed 2- to 3-fold increase for both DRA and
endogenous DRB mRNAs; this phenomenon is also
observed after p5DRB transfection. Taken together,
these results give several indications for the existence of
co-regulation between the two chains: we have observed
an endogenous increase of a chain dependent on the
amount of the other chain ectopically expressed. This phe-
nomenon is absent or only weakly underlined when both
or at least one of the regulatory 50- or 30- UTRs are
lacking. The contemporary presence of 50- and 30-UTRs
flanking the coding region of DRA or DRB is able to
induce a strong increase of its own mRNA and an un-
equivocal co-regulation of the related chain.
In Supplementary Figure S1, we showed the kinetics of
mRNA variation until 72 h after transfection for each con-
structs, in which it seems evident that the increase of en-
dogenous messengers is consequent to that of the
exogenous transcription with a little time delay.
To clarify the involvement of 50- and 30-UTRs, we
generated chimeric constructs in which the DRA coding
region has been replaced with the green fluorescent protein
(GFP) cDNA (see Supplementary Table S1). Forty-eight
hours after M14 transfection, we confirmed the GFP expres-
sion by microscopy (data not shown), and we measured the
amount of GFP, DRA and DRB mRNAs by qRT–PCR
(Figure 1C and D) to discriminate the endogenous synthesis
of mRNA. We observed that the plasmid p5GFP3 carrying
both DRA UTRs is able to induce a 5 - and 6-fold increase
of DRA and DRB mRNAs, respectively, whereas the con-
structs p5GFP and pGFP3 lacking one of these regula-
tory regions induce a 2- to 3-fold increase of the same
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endogenous and exogenous mRNAs. When we transfected
pGFP, we did not observe any variation. At the same
time, the presence of both 50- and 30-UTRs flanking the GFP
cDNA induced an increase of its mRNA amount, compared
with the expression of plasmid containing only GFP cDNA
(Figure 1D); the presence of one of the regulatory regions
50- or 30-UTRs showed an intermediate profile. The use of
chimeric plasmid p5GFP3 confirmed that the phenomenon
of co-regulation is dependent on the presence of both 50- and
30-UTR regions that seem to act in a synergistic way, as in
presence of only one UTR, we observe a partial effect. We
can affirm that these regulatory regions are able to induce an
mRNA increase by de novo transcription or stability increase
of the messengers.
To establish whether the co-regulated expression of two
mRNAs is a general mechanism valid for all isotypes of
MHCII molecules, we transfected M14 with p5DQB3 con-
struct carrying the cDNA of HLA-DQB1 gene and its
50- and 30-UTR control regions. We harvested cells at dif-
ferent time points and measured HLA-DQB1 and both
Figure 1. Quantitative analysis of MHCII expression during co-regulation. (A) Cytofluorimetric analysis of HLA-DR surface expression: M14 cells
are stained with HLA-DR FITC-conjugated–specific antibody 48 h after transfection with indicated plasmids. Results are plotted as fold change of
MFI. (B) Quantification of DRA and DRB mRNAs by qRT–PCR of cells transfected in the same experimental conditions. mRNA amount is
plotted as fold change. P-value is relative to pSVK3. qRT–PCR analysis of DRA and DRB mRNAs (C) and GFP mRNA (D) at 48 h after
transfection of M14 with pSVK3, pGFP, p5GFP3, p5GFP and pGFP3. Results are plotted as fold change compared with pSVK3, and
P-value is relative to pGFP. (E) Quantification of HLA-DQB and HLA-DQA1*01 and HLA-DQA1*03 mRNAs alleles by qRT–PCR after
transfection of M14 with p5DQB3 construct. The graph shows fold variation with respect to pSVK3 at 4, 24, 36 and 48 h. (F) Quantification of DRA
and DRB mRNAs by qRT–PCR in primary monocytes cells 6 h after nucleofection with pSVK3 and p5DRA3 plasmids. The graph shows DRA and
DRB mRNA fold variation, and P-value is compared with the control.
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HLA-DQA1*01 and HLA-DQA1*03 mRNAs by qRT–
PCR (Figure 1E); 36 h after transfection, we observed
30-fold increase of DQB mRNA and 16-fold increase of
the DQA1 mRNA expressed by two alleles (*01 and *03).
In conclusion, also for DQ isotype, the ectopic expression
of the messenger encoding one chain increases the en-
dogenous mRNA amount encoding the other chain.
Furthermore, we demonstrated that the co-regulated
expression of two mRNAs encoding the heterodimeric
MHCII molecule is a general mechanism also occurring
in professional APCs. We nucleofected p5DRA3 construct
in Raji B lymphoma cell line and carried out a time course
analysis of mRNAs encoding a and b chain by qRT–PCR.
As observed in M14, we also appreciated in Raji cells an
upregulation of DRB mRNA (Supplementary Figure S2).
In addition, ex vivo primary monocytes prepared from a
blood sample of a healthy donor were transfected by
nucleofection with p5DRA3, and cells were harvested
6 h afterwards for measurement of DRA and DRB
mRNAs (Figure 1F). The graph shows 4-fold increase of
DRA mRNA, derived from both transfected and en-
dogenous cDNAs, and a linked 2.5-fold change of en-
dogenous DRB mRNA (P< 0.05 and P< 0.01,
respectively).
Our data support, for the first time, the existence of a
mechanism in which the expression of a heterodimeric
protein, derived by the translation of two independent
transcripts, is regulated through the reciprocal balance
of these transcripts. This co-regulation, highlighted in pro-
fessional and non-professional in vitro APC and in ex vivo
monocytes, can involve transcriptional and post-
transcriptional events.
The MHC II mRNAs co-regulation occurs through
transcriptional and post-transcriptional events
To assess the contribution of the transcription to the
co-regulation mechanism, we have analysed whether the
increase of the endogenous mRNA after transfection is
caused by a greater activity of PolII on the MHCII
promoter. To address this, we transfected M14 cell line
with p5DRB3 and p5DRB plasmids, and, 48 h after-
wards, we performed a ChIP assay with an anti-RNA
PolII antibody to analyse the transcriptional activity on
endogenous DRA promoter, in such a manner to deter-
mine the endogenous a DRA mRNA synthesis. In
Figure 2A, we reported the fold occupancy by PolII on
DRA promoter after transfection of two constructs
compared with empty pSVK3 plasmid. We found that,
after transfection by p5DRB3 construct, there is an
increase of a chain endogenous transcription of 0.5
with respect to the control (P< 0.05), but we did not
observe any variation when we transfected the 30-UTR–
deleted plasmid. When an mRNA coding for a single
MHCII chain is overexpressed, the cells reach a balance
in the amount of both messengers through a transcrip-
tional increase of the other related gene; this mechanism
is possible only if the mRNA has an intact 30-UTR.
To unravel the events occurring at a post-
transcriptional level, we investigated the nucleus–cyto-
plasm export of two messengers encoding for the same
isotype. We transfected M14 cells with full-length and
deleted constructs, and we monitored the variation in
the mRNA content in cytoplasmic versus nuclear fractions
at 48 h after transfections. The results are shown in
Figure 2B as a cytoplasmic/nuclear (C/N) ratio. This
ratio is established equal to 1 after transfection with
p5DRA3 construct, increasing to almost 2 when we trans-
fected p5DRA or pDRA3 (statistically significant
versus p5DRA3) and to 4.5 when both UTRs are absent
(pDRA transfection, P< 0.01) without significant
differences between DRA and DRB mRNAs. Similar dif-
ferences are shown in Figure 2C for the other transcript,
comparing the ratio obtained for p5DRB3 and p5DRB
(P< 0.05); export of b-actin mRNA remained unchanged
(data not shown). The trend of the ratio indicates that the
export rate of two messengers is balanced and
coordinated, and the UTRs influence the speed of trans-
port out of nucleus, according to data previously pub-
lished (17).
Furthermore, we evaluated the kinetics of mRNA decay
in cells transfected for 48 h with p5DRA3 and p5DRB3,
whose transcription we have blocked with Act D
treatment for 2, 4 and 6 h. Total mRNA was analysed
for DRA and DRB by qRT–PCR, and results
were normalized to the b-actin mRNA levels and ex-
pressed as percentage of maximum. First, we calculated
(T1/2=Ln(0.5)/slope) the half-lives of endogenous
mRNAs in cells transfected with empty vector pSVK3
(Figure 3A), and we found that DRA mRNA
(t1/2=3.24 h) was more stable than DRB mRNA
(t1/2=2.6 h). Next we analysed the steady-state of
mRNAs in cells transfected with full-length constructs,
and we found that after p5DRA3 ectopic expression
(Figure 3B), there was a significant half-life increase of
both DRA (t1/2=3.92 h) and endogenous DRB
(t1/2=3.19 h) mRNAs, compared with those of cells
transfected with pSVK3 (P< 0.05 and P< 0.01, respect-
ively). Similarly after p5DRB3 transfection (Figure 3C),
we found an analogous half-life increase of endogenous
DRA (t1/2=4.02 h) and DRB (t1/2=3.41 h) transcripts,
compared with the control (P< 0.05 and P< 0.01, respect-
ively). In conclusion, the ectopic expression of a
full-length mRNA encoding a or b chain induces stability
increase of the proper and of the mRNA encoding the
cognate chain, indicating a coordinated regulation of the
decay of the two mRNAs.
We also measured the half-life of GFP after transfection
of chimeric plasmids. Using pGFP, we measured
t1/2=1.9 h (Figure 3D); after p5GFP3 transfection,
there was an evident increase of its half-life
(t1/2=3.71 h), whereas the presence of only one regula-
tory region 50- or 30-UTR showed an intermediate
profile, with t1/2=2.86 and 2.77 for p5GFP and
pGFP3, respectively. GFP mRNA with both UTRs is
more stable with respect to GFP mRNA lacking these
sequences. Finally, (Figure 3E), we reported the half-life
of endogenous DRB mRNA after GFP chimeric con-
structs transfection. When we transfected pGFP, we
measured t1/2=2.58 h of DRB mRNA, equal to half-life
assessed in control cells; after the expression of constructs
with only one regulatory region, p5GFP and pGFP3,
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the DRB half-life increased to t1/2=3 and to t1/2=2.89 h,
respectively. p5GFP3 transfection showed a strong
half-life increase of endogenous DRB mRNA
(t1/2=3.46 h), similar to results obtained transfecting
p5DRA3 (3B). These data indicate that the presence of
UTR sequences stabilizes both MHCII transcripts and
no related messenger.
In conclusion, our experiments indicate that after the
ectopic expression of full-length MHCII cDNA encoding
one chain, there is an augment of mRNAs half-lives of the
endogenous transcript encoding for the other chain,
indicating a coordinate modulation of stability and an
‘in trans’ effect. Moreover, we have observed an ‘in cis’
effect of UTRs regulatory regions on the modulation of
endogenous DRA and DRB genes expression.
The depletion of EBP1 and NF90 influences DRA and
DRB mRNAs expression
In a previous article (7), we demonstrated that the specific
silencing of EBP1 (Figure 4A-I) and NF90 (Figure 4A-II)
induces the downregulation of both DRA and DRB
mRNAs. To assess the contribution of EBP1 and NF90
proteins to the co-regulation of a and b chains, we per-
formed EBP1 and NF90 knockdown experiments
followed by transfections of p5DRA3 or p5DRB3 con-
structs, and we monitored DRA and DRB mRNAs vari-
ation by qRT–PCR. After 24 h of silencing with siCtlr,
siEBP1 and siNF90, we transfected p5DRA3 or
p5DRB3 constructs, and cells were harvested for mRNA
quantification at 6, 18 and 42 h of plasmid transfection
(corresponding to 30, 48 and 72 h from the beginning of
the experiment).
We established that EBP1 and NF90 silencing inhibits
the overexpression of ectopic mRNAs (p5DRA3 in A-V
and A-VII, p5DRB3 in A-VI and A-VIII), and conse-
quently that of endogenous mRNAs compared with
siCtlr (A-III and A-IV). Either EBP1 or NF90 silencing
inhibits the co-regulation mechanism blocking mRNA
increase, induced by transfection, avoiding the mechanism
of co-regulated expression of DRA and DRB transcripts.
Figure 2. ChIP assay and nucleus–cytoplasm export during MHC II mRNA co-regulation. (A) HLA-DRA promoter occupancy by PolII was
analysed by ChIP assay in M14 cells at 48 h from transfection with full-length p5DRB3 or p5DRB-deleted constructs. The histograms represent
the fold variation compared with pSVK3, which indicates the basal rate of DRA transcription. P-value is related to pSVK3. (B) and (C)
Quantification by qRT–PCR of cytoplasmic and nuclear DRA and DRB mRNAs in M14 cells at 48 h after transfection with indicated plasmids.
Results are plotted as cytoplasm/nucleus (C/N) mRNA ratio in two compartments, and P-value is related to p5DRA3 (B) or p5DRB3 (C), which we
consider equal to 1.
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Relative contribution of DRA and DRB messengers
to MHCII density
We tested the relative DRA and DRB mRNAs contribu-
tion to the MHCII heterodimer density in HeLa cell line in
which the MHCII molecules are not constitutively ex-
pressed. We transiently transfected p5DRA3 and
p5DRB3 in HeLa cells, maintaining a fixed amount of
one chain while changing the amount of the other and
evaluated the modulation of DR surface expression, rep-
resented as mean fluorescence intensity (MFI) fold vari-
ation in B-I of Figure 4. In particular, using a constant
amount of p5DRA3 (3 mg) and a variable amount of
p5DRB3 (3, 2 and 1 mg), we measured a decreasing
HLA-DR surface density. When we used a constant
amount of p5DRB3 (3 mg) and a variable amount of
p5DRA3 (3, 2 and 1 mg), we appreciated a more rapid
and significant MFI decrease than that observed when
we scale down p5DRB3 (P< 0.05). Then we looked at
differences in the DRA and DRB total mRNAs and
observed (Figure 4B-II) that both mRNAs varied in a
coordinated manner, according to the smallest amount
of messenger, even with excess of the other. In addition
we noted that, in both protein and mRNA expression,
there are different kinetics, in that the transfection with
decreasing p5DRA3 amount determines a more rapid and
significant reduction of HLA-DRB mRNA (P< 0.01)
compared with the transfection carried out with
decreasing p5DRB3 amount that determines a slower
and not significant variation of HLA-DRA mRNA. In
other words, the expression of DRA mRNA has a preva-
lent role in the establishment of a stoichiometric ratio
between the two transcripts and provides a major contri-
bution to the determination of heterodimer density. This
modulation could be due to the higher stability of DRA
compared with DRB, as reported in the previous experi-
ment, probably a consequence of a different interaction
with proteins of the operon.
50-UTRs take part in the RNP complex
We have previously demonstrated that DRA and DRB
mRNAs, such as DQA mRNA, are included in a
ribonucleoproteic complex, in which 30-UTRs of MHCII
messengers bind to EBP1 and NF90 proteins, among
other not yet identified proteins (7). To investigate the
involvement of 50-UTR of DRA and DRB transcripts
in the RNP complex, we first performed RNA-
Electrophoretic mobility shift assay (REMSA) using cyto-
plasmic protein extracts. We have designed two
riboprobes, corresponding to 50-UTR sequences
upstream of the ATG initiation codon of DRA and
DRB mRNAs, named 5DRA and 5DRB, respectively
(see Supplementary Table S3 for sequences). REMSAs
Figure 3. DRA and DRB mRNA half-lives during co-regulation. Kinetics of DRA and DRB mRNAs decay in M14 cells assessed 48 h after pSVK3
(A), p5DRA3 (B) and p5DRB3 (C) transfections. The cells were harvested after 2, 4 and 6 h of Act D treatment, and the percentages of remaining
mRNAs are showed. Kinetics of GFP (D) and DRB (E) mRNA decay in M14 cells assessed 48 h after p5GFP3, p5GFP, pGFP3 and pGFP
transfections. The cells were harvested after 2, 4 and 6 h of Act D treatment, and the percentages of remaining mRNAs are showed. The half-life of
mRNAs, shown in parentheses, was calculated with the following formula T1/2=Ln(0.5)/slope, indicating the required time for a given transcript to
decrease to 50% of its initial abundance.
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were carried out using S100 extracts from both Raji (data
not shown) and M14 cell lines (Figure 5), and results
showed a clear interaction between cytoplasmic proteins
and 5DRA (A, lane 3) and 5DRB (B, lane 3) riboprobes.
In addition, we performed competition experiments
between the 50- and 30-UTR proper or of the other
chain; as shown in A, the binding to 5DRA riboprobe
was completely displaced by 3DRA (lanes 7–9), and
with lesser extent by 5DRB (lanes 4–6) and 3DRB (lanes
10–12) cold riboprobes. Panel B shows that the
cytoplasmic proteins interaction with 5DRB was displaced
by 3DRA (lanes 10–12), 5DRA (lanes 4–6) and 3DRB
(lanes 7–9) cold riboprobes in a similar manner. This ex-
periment allows us to conclude that 50-UTRs are able to
interact with the same proteins if incubated with cytoplas-
mic extracts, although with different affinity. Moreover,
we observed that the 30-UTR of the DRA chain is always
the strongest competitor, suggesting a prevalent role
of this chain, according to the analysis of stability
(Figure 3) and data obtained in HeLa cells (Figure 4B).
Figure 4. Modulation of MHCII expression. (A) The graphs illustrate the time course (0, 30, 48 and 72 h) of DRA and DRB mRNAs fold variation
in M14 cells measured by qRT–PCR after 24 h of EBP1 and NF90 proteins silencing and subsequent transfections of indicated plasmids. In details,
subpanels show quantification of two messengers after silencing of EBP1 (I) and NF90 (II) and after silencing with siCtrl followed by p5DRA3 (III)
and p5DRB3 (IV) transfections. Silencing with siEBP1 followed by p5DRA3 (V) and p5DRB3 (VI) transfections, and knockdown with siNF90
followed by p5DRA3 (VII) and p5DRB3 (VIII) transfections were shown. (B) (I) Cytofluorimetric analysis of HLA-DR surface expression in HeLa
cells 48 h after transfection with indicated amount of pSVK3, p5DRA3 and p5DRB3 reported as fold change of MFI. (II) DRA and DRB mRNAs
variation measured by qRT–PCR in cells were analysed in the same experimental conditions. In the case of DRB mRNA, P-value is calculated with
respect to the maximum amount of p5DRA3 used; for DRA mRNA, P-value is calculated with respect to the maximum amount of p5DRB3
transfected.
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Then we moved to verify the binding of EBP1 and
NF90 proteins to 5DRA and 5DRB by performing
REMSA with recombinant proteins. The results
reported in Figure 5C show that only 5DRA interacts
with both proteins (lanes 1 and 2), whereas 5DRB inter-
acts with rEBP1 but does not bind rNF90 (lanes 7 and 8).
The supershift assays performed with an anti-DRBP76
antibody confirmed retardation in the mobility of 5DRA
(lanes 4–6) but not of 5DRB (lanes 11–13) with cytoplas-
mic proteins, indicating the exclusion of 5DRB from
binding to NF90 in the RNP complex.
To further validate the interaction of EBP1 and NF90
to 50- and 30-UTRs riboprobes, we performed a biotin
pull-down assay (Figure 5D). In vitro transcribed
biotinylated 5DRA, 5DRB, 3DRA, 3DRB and UBC
(used as negative control) were incubated with M14 cyto-
plasmic proteins. After pull-down with streptavidin-
coated beads, proteins interacting with biotinylated
riboprobes were detected by western blot. The
anti-DRBP76 antibody revealed the presence of both
NF90 and NF110 isoforms (upper panel) in the samples
precipitated by 5DRA, 3DRA and 3DRB, but not in
samples precipitated with 5DRB. The same biotinylated
riboprobes were incubated with cytoplasmic protein
lysates from stable transfected M14–EBP1–FLAG cells,
and the interaction with specific protein was revealed by
anti-FLAG (middle panel) and anti-EBP1 antibodies
(lower panel), demonstrating the binding of all UTRs to
EBP1. The pull-down assay confirmed the direct inter-
action of UTRs MHCII with EBP1 and NF90 proteins,
except the binding of 5DRB to NF90. In conclusion,
beyond the previously identified 30-UTRs, we confirmed
the inclusion of 50-UTRs as cis elements of the MHCII
RNA operon, interacting with EBP1, NF90 and other not
yet identified protein factors.
Common motifs were found in the UTRs of DRA
and DRB mRNAs
We performed a computational analysis of 50- and 30-
UTRs of DRA and DRB mRNAs to find any common
Figure 5. Analysis of interactions of MHCII RNP components. (A) REMSAs experiments performed using 5DRA (lane 1) riboprobe; lane 2 shows
the digestion with T1 RNase. Lane 3 shows the band of interaction of M14 extract with 5DRA. Competition experiments of 5DRA binding were
performed using 0.5, 1 and 2.5 mg of cold 5DRB (lanes 4–6), 3DRA (lanes 7–9) and 3DRB (lanes 10–12). (B) REMSAs experiments performed using
5DRB (lane 1) riboprobe; lane 2 shows the digestion with T1 RNase. Lane 3 shows band of interaction of M14 extract with 5DRB. Competition
experiments of 5DRB binding were performed using 0.5, 1 and 2.5 mg of cold 5DRA (lanes 4–6), 3DRB (lanes 7–9) and 3DRA (lanes 10–12).
(C) REMSAs experiments performed using 5DRA (on the left) and 5DRB (on the right) riboprobes. Lane 1 shows the interaction with rEBP1, lane 2
with rNF90 and lane 3 shows band of binding with M14 extract, whereas lanes 4–6 show the supershift of cytoplasmic complex with anti-DRBP76 in
binding reaction containing 0.25, 1.25 and 2.5 mg of anti-DRBP76 antibody. No supershift was evident in the presence of 2.5 mg of control IgG (lane
7). Lane 8 shows the interaction of 5DRB with rEBP1, lane 9 demonstrates the absence of binding with rNF90, lanes 10 shows band of interaction of
M14 extract, whereas no supershift of cytoplasmic complex with anti-DRBP76 was found in binding reaction containing 0.25, 1.25 and 2.5 mg of
anti-DRBP76 antibody (lanes 11–13), similar to that observed in the presence of 2.5 mg of control IgG (lane 14). (D) Western blot analysis of biotin
pull-down assay carried by using 5DRA, 5DRB, 3DRA, 3DRB and UBC biotinylated riboprobes, after incubation whit cytoplasmic lysate from
M14 cells. The top panel represents the immunoblot performed by anti-NF90, whereas the middle and the bottom panels correspond to the western
carried out by anti-FLAG and anti-EBP1, respectively, able to detect EBP1 protein. Molecular weights are indicated.
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sequence and/or structural features within the RNAs. A
FOLDALIGN analysis against all pairs of sequences
revealed common sequence/secondary structure motifs
consistent with functional bridge formation (Figure 6A).
Each structure is locally stable, enhancing the likelihood
of their presence in vivo. Common motifs were found in
DRA between the 50- and 30-UTR, within DRB between
the 50- and 30-UTR, between 5DRA and 3DRB and
between 5DRB and 3DRA (Figure 6B). Each single
protein binds one or more motifs, generating functional
bridges either within one RNA or across two different
RNAs (Figure 6C). The common motifs allow two types
of interactions to take place, first between 50- and 30-UTR
of the same RNA to form an enclosed loop structure
(Figure 6C left), and second interactions across UTRs of
different RNAs to form a heterogeneous complex within
the RNP (Figure 6C right). In the 50-UTR of DRB, the
two predicted structures with major similarity were
overlapping (Figure 6A); therefore, they are unlikely to
co-exist at the same time, and for this reason, 5DRB
seems to be less locally stable than the other motifs pre-
dicted, providing a possible explanation for the absence of
NF90 binding. The choice of formed structures in the
cases of overlap is likely to be dependent on the affinity
or the relative concentrations of the RNA-binding
proteins present. The formation of functional bridges
between the UTRs of DRA and DRB is likely to be de-
pendent on common RNA secondary structure motifs
interacting with the RNA binding domains of the
protein components of the ‘RNA operon’.
RNP complex links a and b chains together
To test how NF90 and EBP1 are able to interconnect
50- and 30-UTRs, we performed a 50–30 co-precipitation ex-
periment. The 30-UTR 32P-labelled riboprobes were
precipitated using biotin-labelled 50-UTR riboprobes in
presence of 0.1, 0.2, 0.4, 0.8 and 1mg of rNF90 or rEBP1
and 1mg BSA. Specifically, streptavidin-beads covered with
biotinylated 5DRA or 5DRB were incubated with
32P-3DRA or 32P-3DRB, previously incubated with
increasing amount of recombinant proteins. In Figure 7,
we observed that 3DRA riboprobe was clearly precipitated
by 5DRA in presence of rNF90 and rEBP1 compared with
BSA (A); otherwise 3DRA was precipitated by 5DRB
riboprobe only in presence of rEBP1 (B).
In addition, 3DRB riboprobe was precipitated by
5DRA (C) in presence of both proteins, whereas it was
precipitated by 5DRB (D) only in presence of rEBP1.
These data demonstrated that rEBP1 and rNF90 bind
simultaneously both the UTRs of the same DRA and
Figure 6. RNA secondary structure motifs. (A) Locations of the common secondary structure motifs between the 50- and 30-UTRs of the same RNA
to form an enclosed loop [(A) HLA-DRA and (C) HLA-DRB] and between the two different RNAs to form a heterogenic complex [(C)
DRA-50-UTR to DRB-30-UTR and (D) DRB-50-UTR to DRA-30-UTR]. In the HLA-DRB 50-UTR, there are two overlapping structures that
are unlikely to be able to co-exist; therefore, only one at any one time can act as a cis-acting signal. (B) The individual RNA secondary structure
motifs arranged in matching pairs. Each motif is locally stable and with a >50% sequence identity. (C) Possible binding modes between the common
secondary structure motifs within the RNP containing EBP1 and NF90. The binding modes are between the 50- and 30-UTR of the same RNA
molecule and between the UTRs of different RNAs.
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DRB messenger and join 50- and 30-UTR of different tran-
scripts, with exception of 5DRB/NF90 interaction.
To further validate the specificity of this interaction and
also to verify whether the stem–loop predicted structures
identified by the computational analysis determine the
intra- and inter- chains binding trough NF90 and EBP1,
we performed another co-precipitation assay using a
reverse labelling of the riboprobes and mutated
riboprobes, named 5DRA and 5DRB. We deleted
40 and 50 bases of 5DRA and 5DRB, respectively
(see sequences in Supplementary Table S3), necessary to
form the predicted stem–loop structures. In this experi-
ment, the 50-UTR or the 50-UTR 32P-labelled riboprobes
were precipitated using biotin-labelled 30-UTR riboprobes
in presence of 1 mg of rNF90, rEBP1 and BSA. We
observed that 32P-5DRA was precipitated by biotinylated
3DRA or 3DRB in presence of rEBP1 and rNF90 (E and
G), whereas 32P-5DRB was precipitated by biotinylated
3DRA or 3DRB only in presence of rEBP1 (F and H),
confirming previous results, whereas both 32P-5DRA
and 32P-5DRB were always unable to precipitate
biotin-labelled 3DRA and 3DRB riboprobes in presence
of any recombinant proteins (E–H) compared with
full-length riboprobes.
The 50–30 co-precipitation assays confirm that rEBP1
binds both UTRs of DRA and DRB mRNAs and links
30-UTR of a messenger with 50-UTR of the other tran-
script. Differently, rNF90 interacts with both terminus
of DRA and allows only the binding of 5DRA with
3DRB. These data suggest that EBP1 and NF90 are
involved in the establishment of functional bridges inside
the RNP complex by connecting 50- and 30-UTRs (see
model in Figure 8).
DISCUSSION
Gene expression is a coordinated process that comprises
different linked steps, such as transcription, RNA process-
ing, nucleus–cytoplasm export, translation and degrad-
ation of mRNAs. Trans-acting factors, interacting with
50-UTRs and 30-UTRs of messengers coordinate these
processes inside the post-transcriptional operon (18).
Many studies support the functional integration of tran-
scription to the splicing, to the 30-end processing (19,20)
Figure 7. The 50–30 co-precipitation assay. All experiments were performed by biotinylated riboprobes, indicated with bio prefix, and 32P-UTP–
labelled riboprobes indicated with 32P prefix. (A–D) Experiments carried out in presence of indicated biotinylated and 32P-riboprobes and 0.1, 0.2,
0.4, 0.8 and 1 mg rNF90 (lanes 1–5), no protein (lanes 6), 1 mg BSA (lane 7) and 1, 0.8, 0.4, 0.2 and 0.1 mg rEBP1 (lanes 8–12). (E–H) Experiments
carried out in presence of indicated biotinylated and 32P-riboprobes without protein (lanes 1 and 5), in presence of 1 mg of BSA (lane 2 and 6), 1mg
rEBP1 (lanes 3 and 7) and 1 mg rNF90 (lanes 4 and 8).
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and to mRNA export (21). The interplay among transcrip-
tional control and mRNA stability directs the temporal
order of induction of genes encoding inflammatory mol-
ecules (22), whereas temporally coordinated changes in
populations of HuR associated mRNAs occur during
T-cell activation (23).
Our work investigated the fate of mRNAs encoding
polypeptides forming MHCII surface heterodimers be-
longing to the HLA-DQ and HLA-DR isotypes. In this
context, we were interested in the open question regarding
the stoichiometric balance of the two mRNAs that will
encode MHCII heterodimeric molecules. We know that
the transcription of DRA and DRB polymorphic genes
is strictly coordinated, but there is a lack of available
data about the events downstream of the transcription.
To unravel this issue, we perturbed the existing equilib-
rium state between two transcripts by the ectopic expres-
sion of a full-length messenger encoding DR a or b chain,
and we observed an increase in the amount of endogenous
mRNAs encoding for the other chain. This phenomenon,
referred as ‘co-regulation’, occurred in both professional
APCs, a Raji B lymphoma cell line and primary mono-
cytes, as well as in non-professional APCs, as M14 cell
lines, also for the DQ isotype. We describe here, for the
first time, a kind of balance that has to be maintained
between two transcripts whose proteins have to be
assembled in a heterodimeric surface molecule, in several
cell types. The cis elements responsible for this co-
regulation are the 50- and 30-UTRs because transfections
performed with cDNA deleted of these regions fail to
induce a clear increase of endogenous-related transcript,
also because of the lower amount of ectopic mRNA
produced. Transfections, with chimeric constructs
carrying GFP coding region fused to 50- and/or 30-UTR
of DRA, allow us to confirm the role of these regulatory
regions that, when provided in trans by a non-related tran-
script, were able to stimulate the increase of both endogen-
ous DRA and DRB mRNAs; the UTR regions are the key
regulators of equilibrium being able per se to induce vari-
ation of their messengers.
To better evaluate the co-regulation, we individually
analysed transcription, export and stability of DRA and
DRB mRNA. By ChIP assay, we have shown an increase
of DRA transcription after the ectopic expression of
full-length DRB, which is not observed using the construct
deleted of 30-UTR. This result shows a function of 30-UTR
on the stimulation of Pol II activity at the DRA promoter
level, probably mediated by a positive feedback on the
transcriptional machinery.
The analysis of cytoplasmic and nuclear mRNA after
transfections demonstrated a coordinated export of both
endogenous and the exogenous DRA and DRB mRNAs.
Figure 8. MHC II RNA operon bridging model. RNP complex binds 50- and 30-UTR of the DRA and DRB mRNAs and links 30-UTR of a messenger
with 50-UTR of the other transcript. This bridging model interplays transcription with RNA processing inside the nucleus and in the cytoplasm.
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In addition, we observed that the depletion of 30- or 50-
UTR augments the ratio of C/N mRNAs, indicating an
increase of the export out of the nucleus already
demonstrated in a previous article by the authors (17).
Concerning the modulation of the stability, we observed
that after ectopic expression of a full-length construct,
there is an increase in half-life of the endogenous messen-
ger encoding the related chain. This increase of stability is
also observed in GFP chimeric constructs in which 5DRA
and 3DRA influence in cis the decay of the exogenous
messenger and in trans the stability of endogenous DRB
transcript. The role of 50- and 30-UTR in the half-life
modulation seems to be equivalent and synergistic
because we have observed an intermediate effect on sta-
bility by the chimeric construct carrying only one UTR.
These results clearly demonstrate that the co-regulation
occurs at different levels of mRNA processing and can be
accomplished thanks to the interaction of UTRs with the
RNA-binding protein complex, of which we have
identified two factors: EBP1 and NF90 (7). NF90
protein, included in the NFARs family, activates tran-
scription of interleukin-2 (IL-2) (10) and IL-13 (24) and
controls the stability and/or export of a wide variety of
RNAs (25), functioning as translational sentinels to detect
viral RNAs and impede their transcription and translation
(26). EBP1, identified as ErbB3-binding protein, is a pleio-
tropic protein, acting as transcriptional repressor on E2F1
consensus promoters and as RNA-binding protein with
the role of stability modulator (9,27). Both proteins are
widely described as RNA-binding proteins, with NF90
able to recognize dsRNA, especially targeting A/U rich
regions of UTRs (28), and EBP1 capable to preferentially
bind structured regions of RNA within RNA complexes
(29,30). Moreover, the function of suppressor or/and
oncogene described for EBP1 (12,31) allows us to hy-
pothesize a relationship between cancer and MHCII-
mediated immune response. This aspect becomes espe-
cially relevant if we consider that in non-professional
APCs, such as cancer cells, the surface expression of
MHCII could consent epitope cancer presentation and
subsequent CD4 immune response to the tumour.
In our system, the depletion of EBP1 and NF90 by
siRNA transfection, inhibits the overexpression of both
ectopic and endogenous MHCII mRNAs, indicating the
fundamental role of these proteins on the modulation of
MHCII expression. Pull-down experiments demonstrate
the direct binding of EBP1 to the 30-UTR and to
50-UTR of both DRA and DRB mRNAs and the inter-
action of NF90 with 5DRA, 3DRA and 3DRB, but not
with 5DRB. This result could be related to other data
concerning DRB messenger: the transfection of constant
amount of a plasmid encoding one mRNA and a variable
quantity of the plasmid encoding the other transcript in
HeLa cells, demonstrates, in fact, not only that the
co-regulation takes place also in cells negative for
MHCII expression but also that the heterodimer surface
density is essentially modulated by DRA mRNA amount
and to a minor extent by DRB mRNA quantity. The
higher stability of the DRA transcript, the greater
affinity of its UTRs for the protein complex and also the
absence of polymorphism with respect to other MHC II
mRNAs, suggests that the main role of this messenger in
the operon context is to establish the balance with its
cognate mRNA.
As reported in the literature, EBP1 is theoretically
capable of binding two separate RNA structured
regions, although it is yet to be observed in vivo (32),
whereas the formation of a loop structure has been
already demonstrated for NF90 associating with both
termini of a viral RNA genome, structure important for
the coordination of translation and replication (33). On
this basis, by a 50/30 co-precipitation assay, we found that
rEBP1, at the same time, interacts with 50- and 30-ends
inside each DRA or DRB transcripts and links 5DRA
to 3DRB and 5DRB to 3DRA. Differently, rNF90 fails
in all the interactions involving 5DRB, according to
REMSA and pull-down assays, whereas it is able to inter-
connect 5DRA to its proper 3DRA and to 3DRB. The
specificity of this interaction is validated by mutagenesis,
as 50-UTRs carrying 40–50 nt deletions were unable to
keep the interactions with 30-UTR.
The mutual relationships inside RNP can be related to
the computational analysis of the RNA secondary struc-
tures that have identified similar motifs in all UTRs of
DRA and DRB. The sequence identity of these motifs is
>50%, supporting the building of a loop conformation of
two mRNAs through several RNA-binding proteins,
giving, in particular, a possible explanation of the recog-
nition of several UTRs by EBP1 and NF90.
RNA-binding proteins, in fact, often comprise multiple
RNA-binding domains building up specificity and affinity
by binding multiple short sites (4–8 nt) on the RNA, and
many RNA-binding domains are also functional as pro-
tein:protein interaction sites (34), such as NF90 (35),
although its tissue-specific isoforms have made the eluci-
dation of RNA target motifs an area of controversy (36).
The RNA secondary structure prediction of the entire
mRNA is not likely to be consistent with the in vivo struc-
ture; however, the local environment around a potential
binding site determines the accessibility and stability of the
motif (37). Furthermore, even if secondary structures are
highly dynamic, they are often stabilized on binding to
their protein partners (38).
Here, we propose a model in which MHCII RNA
operon regulates the stoichiometric balance of the
related DRA and DRB messengers, resulting in a
balanced assembly of a and b polypeptides to obtain a
functional heterodimeric molecule, both for DQ and DR
isotypes (Figure 8). This equilibrium is modulated at
mRNAs level by a complex mechanism involving the tran-
scription and the downstream steps of the mRNAs pro-
cessing. According to the operon model, RNAs are
decorated with proteins throughout their lifetimes in a
highly dynamic structure; we hypothesize that the RNP,
comprising not only EBP1 and NF90 but also other as yet
unidentified proteins, docks the rising DRA and DRB
mRNAs at UTRs level already during transcription, and
it joins together the two chains building functional bridges
during the proceeding processes. In this context, the alter-
ation of the equilibrium through in vitro transfection
induces the RNP machinery to restore the previous
balance influencing the transcriptional rate of the PolII
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complex. Furthermore, the two transcripts are simultan-
eously regulated both for the nucleus–cytoplasm export
and decay in the cytoplasm; in this context, the role of
both UTRs is essential, as they contain the recognition
sites of trans-acting proteins. This scenario has to be
extended for its implications; the artificial perturbation
we have induced can mimic the cell environmental
changes after an activation stimulus. If the cells have to
present antigens and, as consequence, a modulation of
MHCII expression is required, there is a rapid RNP
remodelling that guarantees the coordinate and balanced
processing of the two related transcripts.
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